Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant

Ki Woong Nam, Chi Kyung Kim, Tae Jung Kim, Sang Joon An, Kyungmi Oh, Sang Bae Ko, Byung Woo Yoon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Low-molecular weight heparin (LMWH) was shown to be effective and safe in treating venous thromboembolism, and generally used for stroke in cancer patients, but its effects on stroke are unclear. We compared clinical outcomes between LMWH and new oral anticoagulant (NOAC) in patients with cancer-related stroke. Methods We enrolled patients with cryptogenic ischemic stroke with active cancer who were treated with LMWH or NOAC between May 2012 and June 2015. The clinical outcomes, including early neurologic deterioration, early radiologic recurrence, 3-month modified Rankin scale score, 90-day mortality, cardio-cerebrovascular recurrence, and bleeding complications, were compared. Results Among 48 patients, 7 patients were treated with NOAC, and the remaining 41 patients with LMWH. Overall, the participants presented poor outcomes, including 20 (42%) early neurologic deteriorations, 28 (58%) early radiologic recurrences, 34 (71%) poor modified Rankin scale scores, 27 (56%) 90-day mortality events, 24 (50%) cardio-cerebrovascular recurrences, and 18 (38%) bleeding complications, that led to a change or temporary hold in medication in 12 cases. No statistical differences were found between the 2 groups in terms of demographic, clinical, or cardiovascular risk factors and clinical outcomes. Conclusions NOAC showed the similar clinical outcomes and safety compared with LMWH in the treatment of cryptogenic ischemic stroke in active cancer patients.

Original languageEnglish
Pages (from-to)2976-2980
Number of pages5
JournalJournal of Stroke and Cerebrovascular Diseases
Volume26
Issue number12
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Anticoagulants
Low Molecular Weight Heparin
Stroke
Neoplasms
Recurrence
Nervous System
Therapeutics
Hemorrhage
Mortality
Venous Thromboembolism
Demography
Safety

Keywords

  • anticoagulation
  • cancer
  • hypercoagulability
  • Ischemic stroke
  • NOAC
  • prognosis

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant. / Nam, Ki Woong; Kim, Chi Kyung; Kim, Tae Jung; An, Sang Joon; Oh, Kyungmi; Ko, Sang Bae; Yoon, Byung Woo.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 26, No. 12, 01.12.2017, p. 2976-2980.

Research output: Contribution to journalArticle

Nam, Ki Woong ; Kim, Chi Kyung ; Kim, Tae Jung ; An, Sang Joon ; Oh, Kyungmi ; Ko, Sang Bae ; Yoon, Byung Woo. / Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant. In: Journal of Stroke and Cerebrovascular Diseases. 2017 ; Vol. 26, No. 12. pp. 2976-2980.
@article{039d86d1b597403bb7c39304d2c49ffb,
title = "Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant",
abstract = "Background Low-molecular weight heparin (LMWH) was shown to be effective and safe in treating venous thromboembolism, and generally used for stroke in cancer patients, but its effects on stroke are unclear. We compared clinical outcomes between LMWH and new oral anticoagulant (NOAC) in patients with cancer-related stroke. Methods We enrolled patients with cryptogenic ischemic stroke with active cancer who were treated with LMWH or NOAC between May 2012 and June 2015. The clinical outcomes, including early neurologic deterioration, early radiologic recurrence, 3-month modified Rankin scale score, 90-day mortality, cardio-cerebrovascular recurrence, and bleeding complications, were compared. Results Among 48 patients, 7 patients were treated with NOAC, and the remaining 41 patients with LMWH. Overall, the participants presented poor outcomes, including 20 (42{\%}) early neurologic deteriorations, 28 (58{\%}) early radiologic recurrences, 34 (71{\%}) poor modified Rankin scale scores, 27 (56{\%}) 90-day mortality events, 24 (50{\%}) cardio-cerebrovascular recurrences, and 18 (38{\%}) bleeding complications, that led to a change or temporary hold in medication in 12 cases. No statistical differences were found between the 2 groups in terms of demographic, clinical, or cardiovascular risk factors and clinical outcomes. Conclusions NOAC showed the similar clinical outcomes and safety compared with LMWH in the treatment of cryptogenic ischemic stroke in active cancer patients.",
keywords = "anticoagulation, cancer, hypercoagulability, Ischemic stroke, NOAC, prognosis",
author = "Nam, {Ki Woong} and Kim, {Chi Kyung} and Kim, {Tae Jung} and An, {Sang Joon} and Kyungmi Oh and Ko, {Sang Bae} and Yoon, {Byung Woo}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2017.07.029",
language = "English",
volume = "26",
pages = "2976--2980",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant

AU - Nam, Ki Woong

AU - Kim, Chi Kyung

AU - Kim, Tae Jung

AU - An, Sang Joon

AU - Oh, Kyungmi

AU - Ko, Sang Bae

AU - Yoon, Byung Woo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background Low-molecular weight heparin (LMWH) was shown to be effective and safe in treating venous thromboembolism, and generally used for stroke in cancer patients, but its effects on stroke are unclear. We compared clinical outcomes between LMWH and new oral anticoagulant (NOAC) in patients with cancer-related stroke. Methods We enrolled patients with cryptogenic ischemic stroke with active cancer who were treated with LMWH or NOAC between May 2012 and June 2015. The clinical outcomes, including early neurologic deterioration, early radiologic recurrence, 3-month modified Rankin scale score, 90-day mortality, cardio-cerebrovascular recurrence, and bleeding complications, were compared. Results Among 48 patients, 7 patients were treated with NOAC, and the remaining 41 patients with LMWH. Overall, the participants presented poor outcomes, including 20 (42%) early neurologic deteriorations, 28 (58%) early radiologic recurrences, 34 (71%) poor modified Rankin scale scores, 27 (56%) 90-day mortality events, 24 (50%) cardio-cerebrovascular recurrences, and 18 (38%) bleeding complications, that led to a change or temporary hold in medication in 12 cases. No statistical differences were found between the 2 groups in terms of demographic, clinical, or cardiovascular risk factors and clinical outcomes. Conclusions NOAC showed the similar clinical outcomes and safety compared with LMWH in the treatment of cryptogenic ischemic stroke in active cancer patients.

AB - Background Low-molecular weight heparin (LMWH) was shown to be effective and safe in treating venous thromboembolism, and generally used for stroke in cancer patients, but its effects on stroke are unclear. We compared clinical outcomes between LMWH and new oral anticoagulant (NOAC) in patients with cancer-related stroke. Methods We enrolled patients with cryptogenic ischemic stroke with active cancer who were treated with LMWH or NOAC between May 2012 and June 2015. The clinical outcomes, including early neurologic deterioration, early radiologic recurrence, 3-month modified Rankin scale score, 90-day mortality, cardio-cerebrovascular recurrence, and bleeding complications, were compared. Results Among 48 patients, 7 patients were treated with NOAC, and the remaining 41 patients with LMWH. Overall, the participants presented poor outcomes, including 20 (42%) early neurologic deteriorations, 28 (58%) early radiologic recurrences, 34 (71%) poor modified Rankin scale scores, 27 (56%) 90-day mortality events, 24 (50%) cardio-cerebrovascular recurrences, and 18 (38%) bleeding complications, that led to a change or temporary hold in medication in 12 cases. No statistical differences were found between the 2 groups in terms of demographic, clinical, or cardiovascular risk factors and clinical outcomes. Conclusions NOAC showed the similar clinical outcomes and safety compared with LMWH in the treatment of cryptogenic ischemic stroke in active cancer patients.

KW - anticoagulation

KW - cancer

KW - hypercoagulability

KW - Ischemic stroke

KW - NOAC

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85028310010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028310010&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2017.07.029

DO - 10.1016/j.jstrokecerebrovasdis.2017.07.029

M3 - Article

C2 - 28843806

AN - SCOPUS:85028310010

VL - 26

SP - 2976

EP - 2980

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 12

ER -